Article
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2017
Knebel Franciele H, Bettoni Fabiana, Shimada Andrea K, Cruz Manoel, Alessi João Victor, Negrão Marcelo V, Reis Luiz Fernando L, Katz Artur, Camargo Anamaria A
Abstract excerpt
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance are not yet fully understood. Monitoring and managing NSCLC patients who progressed on osimertinib is, therefore, emerging as an important clinical challenge....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.